OACS Ireland

29/08/2026

CONTACT THE SODIUM ( ) FOR YOUR VOICE TO BE HEARD.. THE INQUIRY WANTS TO HEAR FROM YOU. LINK ⬇️

https://sodiumvalproateinquiry.ie/contact/

27/08/2026

Keep these thoughts, more to come .....

26/08/2026

Time is running out to make your voice heard, with only five days left to register for the Irish Sodium Valproate Inquiry.

Dr Ronan Glynn, Specialist in Public Health Medicine, HSE discusse...

25/08/2026

Check out our post on intergram - Sodium Valproate Inquiry hear our voice the Followers and Viewers

20/08/2026

FB Inquiry page ➡️ Sodium Valproate Inquiry Website:
The Inquiry would like to hear from those with a diagnosis of Foetal Valproate Spectrum Disorder (FVSD), those progressing through the diagnostic pathway, and/or their family members. If you would like to engage with the Inquiry, please find below the following ways to get in touch.

https://sodiumvalproateinquiry.ie/contact/

13/08/2026

With the permission from the family.
OACS Ireland has now lost a grandparent who brought their child to neurology for help in relation to her childs epilepsy. That child was subsequently put on Sodium . The child grew up and had two beautiful children who have been exposed to sodium valproate and have a diagnosis of .

This grandparent will never be able to go before the Chair of the Sodium Valproate Inquiry to give her testimony. We are losing grandparents of children with FVSD. Unfortunately, time is running out for them.

We urge all grandparents to write down their experiences of bringing their child to , who now have grandchildren with a diagnosis of FVSD. Our sincere condolences to the family in question.

06/08/2026

Check out OACS Ireland Instagram page.
Sodium Valproate Inquiry

18/06/2026

EMA Holds Precautions Despite Mixed Evidence.

Unresolved Evidence Drives Continued Caution:

The most recent review was triggered in July 2025 after publication of a Danish nationwide registry-based study that found no increased NDD risk in children born to men treated with valproate. In reassessing the full evidence base, PRAC concluded that differences in study design — including patient selection criteria and approaches to controlling for underlying health conditions — probably account for much of the variation in findings.

PRAC could not determine whether a potential risk for NDDs in children of fathers treated with valproate before conception results from valproate or other factors, such as the fathers’ underlying medical condition. In light of remaining uncertainties and pending results of an ongoing study expected in 2028, PRAC agreed that precautionary measures introduced in 2024 should remain in place.

EMA has found inconsistent data on developmental disorders in children of fathers using valproate before conception and retains existing precautions.

21/05/2026

Today, members of the OACS Ireland Board, accompanied by, Boylan’s litigation gave evidence before the Sodium Valproate Inquiry

11/05/2026

A significant chapter in Irish public health began today as the long-awaited Sodium Inquiry officially commenced for Stakeholders. OACS Ireland attended the first session accompanied by Boylan’s litigation law firm. OACS will be represented every day of the hearings. Theresa Byrne and Karen Keely outstide the hearings today.